Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-26T13:50:41.119Z Has data issue: false hasContentIssue false

Peripheral Neuropathies

from Part II - Neuromuscular Cases

Published online by Cambridge University Press:  29 November 2024

Jessica E. Hoogendijk
Affiliation:
University Medical Center Utrecht
Marianne de Visser
Affiliation:
Amsterdam University Medical Center
Pieter A. van Doorn
Affiliation:
Erasmus MC, University Medical Center, Rotterdam
Erik H. Niks
Affiliation:
Leiden University Medical Center
Get access
Type
Chapter
Information
Neuromuscular Disease
A Case-Based Approach
, pp. 93 - 155
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Doets, AY, Lingsma, HF, Walgaard, C, et al.; IGOS Consortium. Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS Outcome Score. Neurology 2022;98(5):e518e532. doi: 10.1212/WNL.0000000000013139. Epub 2021 Dec 22. PMID: 34937789; PMCID: PMC8826467.CrossRefGoogle ScholarPubMed
Doets, AY, Walgaard, C, Lingsma, HF, et al.; IGOS Consortium. International validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score. Ann Neurol 2022;91(4):521531. doi: 10.1002/ana.26312. Epub 2022 Feb 21. PMID: 35106830; PMCID: PMC9306880.CrossRefGoogle ScholarPubMed
van Doorn, PA, Van den Bergh PYK, Hadden RDM et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol. 2023 Dec;30(12):3646–3674. doi: 10.1111/ene.16073. Epub 2023 Oct 10. PMID: 37814552; J Peripher Nerv Syst. 2023 Dec;28(4):535–563. doi: 10.1111/jns.12594. Epub ahead of print 2023 Oct 10 PMID: 37814552Google Scholar
Leonhard, SE, Mandarakas, MR, Gondim, FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019;15(11):671683. doi: 10.1038/s41582-019-0250-9. Epub 2019 Sep 20. PMID: 31541214; PMCID: PMC6821638.Google ScholarPubMed
Walgaard, C, Jacobs, BC, Lingsma, HF, et al.; Dutch GBS Study Group. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021;20(4):275283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. PMID: 33743237.CrossRefGoogle ScholarPubMed
Walgaard, C, Lingsma, HF, Ruts, L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011;76(11):968975. doi: 10.1212/WNL.0b013e3182104407. PMID: 21403108; PMCID: PMC3059137.CrossRefGoogle ScholarPubMed
Willison, HJ, Jacobs, BC, van Doorn, PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717727. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435.CrossRefGoogle ScholarPubMed

Suggested Reading

Adrichem, ME, Lucke, IM, Vrancken, AFJE, et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain 2022;145(5):1641-1652. doi: 10.1093/brain/awac054. PMID: 35139161; PMCID: PMC9166547.CrossRefGoogle ScholarPubMed
Van den Bergh, PYK, van Doorn, PA, Hadden, RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021 Sep;26(3):242268. doi: 10.1111/jns.12455. Epub 2021 Jul 30. Erratum in: J Peripher Nerv Syst 2022;27(1):94. Erratum in: Eur J Neurol. 2022 Apr;29(4):1288. PMID: 34085743.Bottom of FormCrossRefGoogle ScholarPubMed
Oaklander, AL, Lunn, MP, Hughes, RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 2017;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2. PMID: 28084646; PMCID: PMC5468847.Google ScholarPubMed

Suggested Reading

Carroll, AS, Lunn, MPT. Paraproteinaemic neuropathy: MGUS and beyond. Pract Neurol 2021;21(6):492503. doi: 10.1136/practneurol-2020-002837. Epub 2021 Jul 19. PMID: 34282034.CrossRefGoogle ScholarPubMed
Chaganti, S, Hannaford, A, Vucic, S. Rituximab in chronic immune mediated neuropathies: a systematic review. Neuromuscul Disord 2022;32(8):621627. doi: 10.1016/j.nmd.2022.05.013. Epub 2022 May 24. PMID: 35672205.CrossRefGoogle ScholarPubMed
Lunn, MP, Nobile-Orazio, E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2016;10(10):CD002827. doi: 10.1002/14651858.CD002827.pub4. PMID: 27701752; PMCID: PMC6457998.Google ScholarPubMed
Parisi, M, Dogliotti, I, Clerico, M, et al. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up. Eur J Neurol 2022;29(12):36113622. doi: 10.1111/ene.15553. Epub 2022 Sep 25. PMID: 36083713; PMCID: PMC9825860.CrossRefGoogle ScholarPubMed
Sommer, C, Carroll, AS, Koike, H, et al. Nerve biopsy in acquired neuropathies. J Peripher Nerv Syst 2021;26 Suppl 2:S21S41. doi: 10.1111/jns.12464. Epub 2021 Sep 14. PMID: 34523188.CrossRefGoogle ScholarPubMed
Taams, NE, Drenthen, J, Hanewinckel, R, Ikram, MA, van Doorn, PA. Prevalence and risk factor profiles for chronic axonal polyneuropathy in the general population. Neurology 2022:10.1212/WNL.0000000000201168. doi: 10.1212/WNL.0000000000201168. Epub ahead of print. PMID: 36008153.Google Scholar
Vallat, JM, Duchesne, M, Corcia, P, et al. The wide spectrum of pathophysiologic mechanisms of paraproteinemic neuropathy. Neurology 2021;96(5):214225. doi: 10.1212/WNL.0000000000011324. Epub 2020 Dec 4. PMID: 33277411.CrossRefGoogle ScholarPubMed

Suggested Reading

Bou Zerdan, M, George, TI, Bunting, ST, Chaulagain, CP. Recent advances in the treatment and supportive care of POEMS syndrome. J Clin Med 2022;11(23):7011. doi: 10.3390/jcm11237011. PMID: 36498588; PMCID: PMC9741379.CrossRefGoogle ScholarPubMed
Dispenzieri, A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94(7):812827. doi: 10.1002/ajh.25495. Epub 2019 May 23. PMID: 31012139.CrossRefGoogle ScholarPubMed
D’Sa, S, Khwaja, J, Keddie, S, et al. Comprehensive diagnosis and management of POEMS syndrome. Hemasphere 2022;6(11):e796. doi: 10.1097/HS9.0000000000000796. PMID: 36340912; PMCID: PMC9624442.CrossRefGoogle ScholarPubMed
Khouri, J, Nakashima, M, Wong, S. Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review. JAMA Oncol 2021;7(9):13831391. doi: 10.1001/jamaoncol.2021.0586. PMID: 34081097.CrossRefGoogle ScholarPubMed
Kim, YR. Update on the POEMS syndrome. Blood Res 2022;57(S1):2731. doi: 10.5045/br.2022.2022001. PMID: 35483922; PMCID: PMC9057663.CrossRefGoogle ScholarPubMed

Suggested Reading

Collins, MP, Dyck, PJB, Hadden, RDM. Update on classification, epidemiology, clinical phenotype and imaging of the nonsystemic vasculitic neuropathies. Curr Opin Neurol 2019;32(5):684695. doi: 10.1097/WCO.0000000000000727. PMID: 31313704.CrossRefGoogle ScholarPubMed
Gwathmey, KG, Tracy, JA, Dyck, PJB. Peripheral nerve vasculitis: classification and disease associations. Neurol Clin 2019;37(2):303333. doi: 10.1016/j.ncl.2019.01.013. Epub 2019 Mar 18. PMID: 30952411.CrossRefGoogle ScholarPubMed
Koike, H, Nishi, R, Ohyama, K, et al. ANCA-associated vasculitic neuropathies: a review. Neurol Ther 2022;11(1):2138. doi: 10.1007/s40120-021-00315-7. Epub 2022 Jan 19. PMID: 35044596; PMCID: PMC8857368.CrossRefGoogle ScholarPubMed

Suggested Reading

Chan, ACY, Kumar, S, Tan, G, et al. Expanding the genetic causes of small-fiber neuropathy: SCN genes and beyond. Muscle Nerve 2023;67(4):259271. doi: 10.1002/mus.27752. Epub 2022 Nov 30. PMID: 36448457.CrossRefGoogle ScholarPubMed
Devigili, G, Cazzato, D, Lauria, G. Clinical diagnosis and management of small fiber neuropathy: an update on best practice. Expert Rev Neurother 2020;20(9):967980. doi: 10.1080/14737175.2020.1794825. Epub 2020 Jul 23. PMID: 32654574.CrossRefGoogle ScholarPubMed
Geerts, M, de Greef, BTA, Sopacua, M, et al. Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 2021;96(20):e2534e2545. doi: 10.1212/WNL.0000000000011919. Epub 2021 Mar 25. PMID: 33766992; PMCID: PMC8205474.CrossRefGoogle ScholarPubMed
Hoeijmakers, JGJ, Merkies, ISJ, Faber, CG. Small fiber neuropathies: expanding their etiologies. Curr Opin Neurol 2022;35(5):545552. doi: 10.1097/WCO.0000000000001103. Epub 2022 Aug 11. PMID: 35950732.Google ScholarPubMed
Sopacua, M, Hoeijmakers, JGJ, Merkies, ISJ, et al. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst 2019;24(1):1933. doi: 10.1111/jns.12298. Epub 2019 Jan 8. PMID: 30569495.CrossRefGoogle ScholarPubMed
Terkelsen, AJ, Karlsson, P, Lauria, G, et al. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16(11):934944. doi: 10.1016/S1474-4422(17)30329-0. Erratum in: Lancet Neurol. 2017 Dec;16(12):954. PMID: 29029847.CrossRefGoogle ScholarPubMed

Suggested Reading

Amato, AA, Ropper, AH. Sensory ganglionopathy. i 2020;383(17):16571662. doi: 10.1056/NEJMra2023935. PMID: 33085862.Google ScholarPubMed
Antoine, JC. Sensory neuronopathies, diagnostic criteria and causes. Curr Opin Neurol 2022;35(5):553561. doi: 10.1097/WCO.0000000000001105. Epub 2022 Aug 11. PMID: 35950727.Google ScholarPubMed
Camdessanché, JP, Jousserand, G, Ferraud, K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009;132:17231733. doi: 10.1093/brain/awp136. Epub 2009 Jun 8. PMID: 19506068; PMCID: PMC2702838.CrossRefGoogle ScholarPubMed
Fargeot, G, Echaniz-Laguna, A. Sensory neuronopathies: new genes, new antibodies and new concepts. J Neurol Neurosurg Psychiatry 2021;jnnp-2020-325536. doi: 10.1136/jnnp-2020-325536. Epub ahead of print. PMID: 33563795.CrossRefGoogle Scholar
Graus, F, Vogrig, A, Muñiz-Castrillo, S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021;8(4):e1014. doi: 10.1212/NXI.0000000000001014. PMID: 34006622; PMCID: PMC8237398.CrossRefGoogle ScholarPubMed
Titulaer, MJ, Soffietti, R, Dalmau, J, et al.; European Federation of Neurological Societies.Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18(1):19–e3. doi: 10.1111/j.1468-1331.2010.03220.x. Epub 2010 Sep 29. PMID: 20880069; PMCID: PMC3086523.CrossRefGoogle ScholarPubMed

Suggested Reading

Collins, MP, Hadden, RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol 2017;13(5):302316. doi: 10.1038/nrneurol.2017.42. PMID: 28447661.Google ScholarPubMed
Herraets, IJT, Goedee, HS, Telleman, JA, et al. High-resolution ultrasound in patients with Wartenberg’s migrant sensory neuritis, a case-control study. Clin Neurophysiol 2018;129(1):232237. doi: 10.1016/j.clinph.2017.10.040. Epub 2017 Nov 21. PMID: 29202391.CrossRefGoogle ScholarPubMed
Stork, AC, van der Meulen, MF, van der Pol, WL, et al. Wartenberg’s migrant sensory neuritis: a prospective follow-up study. J Neurol 2010;257(8):13441348. doi: 10.1007/s00415-010-5530-7. Epub 2010 Mar 31. PMID: 20354714; PMCID: PMC2910306.CrossRefGoogle ScholarPubMed

Suggested Reading

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. J Peripher Nerv Syst 2010;15(4):295301. doi: 10.1111/j.1529-8027.2010.00290.x. PMID: 21199100.CrossRefGoogle Scholar
Keddie, S, Eftimov, F, van den Berg, LH, et al. Immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev 2022;1(1):CD004429. doi: 10.1002/14651858.CD004429.pub3. PMID: 35015296; PMCID: PMC8751207.Google ScholarPubMed
Oudeman, J, Eftimov, F, Strijkers, GJ, et al. Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. Neurology 2020;94(1):e62e74. doi: 10.1212/WNL.0000000000008697. Epub 2019 Dec 11. PMID: 31827006.CrossRefGoogle ScholarPubMed
Telleman, JA, Herraets, IJ, Goedee, HS, van Asseldonk, JT, Visser, LH. Ultrasound scanning in the diagnosis of peripheral neuropathies. Pract Neurol 2021;21(3):186195. doi: 10.1136/practneurol-2020-002645. Epub 2021 Feb 4. PMID: 33541914.CrossRefGoogle ScholarPubMed
Vlam, L, van der Pol, WL, Cats, EA, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2011;8(1):4858. doi: 10.1038/nrneurol.2011.175. PMID: 22105211.CrossRefGoogle ScholarPubMed
Yeh, WZ, Dyck, PJ, van den Berg, LH, Kiernan, MC, Taylor, BV. Multifocal motor neuropathy: controversies and priorities. J Neurol Neurosurg Psychiatry 2020;91(2):140148. doi: 10.1136/jnnp-2019-321532. Epub 2019 Sep 11. PMID: 31511307.CrossRefGoogle ScholarPubMed

Suggested Reading

De Wel, B, Claeys, KG. Neuromuscular hyperexcitability syndromes. Curr Opin Neurol 2021;34(5):714720. doi: 10.1097/WCO.0000000000000963. PMID: 34914668.CrossRefGoogle ScholarPubMed
Sawlani, K, Katirji, B. Peripheral nerve hyperexcitability syndromes. Continuum (Minneap Minn) 2017;23(5, Peripheral Nerve and Motor Neuron Disorders):14371450. doi: 10.1212/CON.0000000000000520. PMID: 28968370.Google ScholarPubMed

Suggested Reading

IJspeert, J, Janssen, RMJ, van Alfen, N. Neuralgic amyotrophy. Curr Opin Neurol 2021;34(5):605612. doi: 10.1097/WCO.0000000000000968. PMID: 34054111.CrossRefGoogle ScholarPubMed
Janssen, RMJ, Lustenhouwer, R, Cup, EHC, et al. Effectiveness of an outpatient rehabilitation programme in patients with neuralgic amyotrophy and scapular dyskinesia: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2023;94(6):474481. doi: 10.1136/jnnp-2022-330296. Epub 2023 Jan 25. PMID: 36697215.CrossRefGoogle ScholarPubMed
Klein, CJ, Barbara, DW, Sprung, J, Dyck, PJ, Weingarten, TN. Surgical and postpartum hereditary brachial plexus attacks and prophylactic immunotherapy. Muscle Nerve 2013;47(1):2327. doi: 10.1002/mus.23462. Epub 2012 Oct 5. PMID: 23042485; PMCID: PMC3528817.CrossRefGoogle ScholarPubMed
van Eijk, JJJ, Dalton, HR, Ripellino, P, et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. Neurology 2017;89(9):909917. doi: 10.1212/WNL.0000000000004297. Epub 2017 Aug 2. PMID: 28768846.CrossRefGoogle ScholarPubMed

Suggested Reading

Feldman, EL, Callaghan, BC, Pop-Busui, R, et al. Diabetic neuropathy. Nat Rev Dis Primers 2019;5(1):41. doi: 10.1038/s41572-019-0092-1. PMID: 31197153.CrossRefGoogle ScholarPubMed
Izenberg, A, Perkins, BA, Bril, V. Diabetic neuropathies. Semin Neurol 2015;35(4):424430. doi: 10.1055/s-0035-1558972. Epub 2015 Oct 6. PMID: 26502765.Google ScholarPubMed
Ng, PS, Dyck, PJ, Laughlin, RS, et al. Lumbosacral radiculoplexus neuropathy: incidence and the association with diabetes mellitus. Neurology 2019;92(11):e1188e1194. doi: 10.1212/WNL.0000000000007020. Epub 2019 Feb 13. PMID: 30760636; PMCID: PMC6511105.CrossRefGoogle ScholarPubMed

Suggested Reading

Hamel, J, Logigian, EL. Acute nutritional axonal neuropathy. Muscle Nerve 2018;57(1):3339. doi: 10.1002/mus.25702. Epub 2017 Jun 19. PMID: 28556429.CrossRefGoogle ScholarPubMed
Hanewinckel, R, van Oijen, M, Ikram, MA, van Doorn, PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016;31(1):520. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23. PMID: 26700499; PMCID: PMC4756033.CrossRefGoogle ScholarPubMed
Julian, T, Glascow, N, Syeed, R, Zis, P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol 2019;266(12):29072919. doi: 10.1007/s00415-018-9123-1. Epub 2018 Nov 22. PMID: 30467601; PMCID: PMC6851213.CrossRefGoogle ScholarPubMed

Suggested Reading

Hanewinckel, R, van Oijen, M, Ikram, MA, van Doorn, PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol 2016 Jan;31(1):520. doi: 10.1007/s10654-015-0094-6. Epub 2015 Dec 23. PMID: 26700499; PMCID: PMC4756033.CrossRefGoogle ScholarPubMed
Hanewinckel, R, van Oijen, M, Taams, NE, et al. Diagnostic value of symptoms in chronic polyneuropathy: the Erasmus Polyneuropathy Symptom Score. J Peripher Nerv Syst 2019;24(3):235241. doi: 10.1111/jns.12328. Epub 2019 Jul 9. PMID: 31172622.CrossRefGoogle ScholarPubMed
Taams, NE, Drenthen, J, Hanewinckel, R, Ikram, MA, van Doorn, PA. Prevalence and risk factor profiles for chronic axonal polyneuropathy in the general population. Neurology 2022:10.1212/WNL.0000000000201168. doi: 10.1212/WNL.0000000000201168. Epub ahead of print. PMID: 36008153.Google Scholar
Visser, NA, Notermans, NC, Linssen, RS, van den Berg LH, , Vrancken, AF. Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 2015;84(3):259264. doi: 10.1212/WNL.0000000000001160. Epub 2014 Dec 12. PMID: 25503982.CrossRefGoogle ScholarPubMed
Vrancken, AF, Franssen, H, Wokke, JH, Teunissen, LL, Notermans, NC. Chronic idiopathic axonal polyneuropathy and successful aging of the peripheral nervous system in elderly people. Arch Neurol 2002;59(4):533–340. doi: 10.1001/archneur.59.4.533. PMID: 11939887.CrossRefGoogle ScholarPubMed

Suggested Reading

Kress, JP, Hall, JB. ICU-acquired weakness and recovery from critical illness. N Engl J Med 2014;370(17):16261635. doi: 10.1056/NEJMra1209390. PMID: 24758618.CrossRefGoogle ScholarPubMed
Vanhorebeek, I, Latronico, N, Van den Berghe, G. ICU-acquired weakness. Intensive Care Med 2020;46(4):637653. doi: 10.1007/s00134-020-05944-4. Epub 2020 Feb 19. PMID: 32076765; PMCID: PMC7224132.CrossRefGoogle ScholarPubMed

Suggested Reading

Orr, CF, Ahlskog, JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009;66(7):865869. doi: 10.1001/archneurol.2009.96. PMID: 19597088.CrossRefGoogle ScholarPubMed
Peters, J, Staff, NP. Update on toxic neuropathies. Curr Treat Options Neurol 2022;24(5):203216. doi: 10.1007/s11940-022-00716-5. Epub 2022 Apr 6. PMID: 36186669; PMCID: PMC9518699.CrossRefGoogle ScholarPubMed
Smyth, D, Kramarz, C, Carr, AS, Rossor, AM, Lunn, MP. Toxic neuropathies: a practical approach. Pract Neurol 2023;23(2):120130. doi: 10.1136/pn-2022-003444. Epub 2023 Jan 25. PMID: 36697225.CrossRefGoogle ScholarPubMed
Stähli, BE, Schwab, S. Amiodarone-induced skin hyperpigmentation. QJM 2011;104(8):723724. doi: 10.1093/qjmed/hcq131. Epub 2010 Jul 30. PMID: 20675394.CrossRefGoogle ScholarPubMed
Vassallo, P, Trohman, RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298(11):13121322. doi: 10.1001/jama.298.11.1312. PMID: 17878423.CrossRefGoogle ScholarPubMed

Suggested Reading

Dutta, A, Hunter, JV, Vallejo, JG. Bannwarth syndrome: a rare manifestation of pediatric Lyme neuroborreliosis. Pediatr Infect Dis J 2021;40(11):e442e444. doi: 10.1097/INF.0000000000003245. PMID: 34636801.CrossRefGoogle ScholarPubMed
Garcia-Monco, JC, Benach, JL. Lyme neuroborreliosis: clinical outcomes, controversy, pathogenesis, and polymicrobial infections. Ann Neurol 2019;85(1):2131. doi: 10.1002/ana.25389. PMID: 30536421; PMCID: PMC7025284.Google ScholarPubMed
Kortela, E, Kanerva, MJ, Puustinen, J, et al. Oral doxycycline compared to intravenous ceftriaxone in the treatment of Lyme neuroborreliosis: a multicenter, equivalence, randomized, open-label trial. Clin Infect Dis 2021;72(8):13231331. doi: 10.1093/cid/ciaa217. PMID: 32133487.CrossRefGoogle ScholarPubMed
Nordberg, CL, Bodilsen, J, Knudtzen, FC, et al.; DASGIB study group.Lyme neuroborreliosis in adults: a nationwide prospective cohort study. Ticks Tick Borne Dis 2020;11(4):101411. doi: 10.1016/j.ttbdis.2020.101411. Epub 2020 Feb 24. PMID: 32178995.CrossRefGoogle ScholarPubMed
van Samkar, A, Bruinsma, RA, Vermeeren, YM, et al. Clinical characteristics of Lyme neuroborreliosis in Dutch children and adults. Eur J Pediatr 2023;182(3):11831189. doi: 10.1007/s00431-022-04749-5. Epub 2023 Jan 6. PMID: 36607413.CrossRefGoogle ScholarPubMed

Suggested Reading

Giesel, LM, Hökerberg, YHM, Pitta, IJR, et al. Clinical prediction rules for the diagnosis of neuritis in leprosy. BMC Infect Dis 2021;21(1):858. doi: 10.1186/s12879-021-06545-2. PMID: 34425777; PMCID: PMC8381570.CrossRefGoogle ScholarPubMed
Tomaselli, PJ, Dos Santos, DF, Dos Santos, ACJ, et al. Primary neural leprosy: clinical, neurophysiological and pathological presentation and progression. Brain 2022;145(4):14991506. doi: 10.1093/brain/awab396. PMID: 34664630.CrossRefGoogle ScholarPubMed
World Health Organization. Towards Zero Leprosy: Global Leprosy (Hansen’s Disease) Strategy 2021–2030. (who.int). Jan 27, 2023. ISBN: 978 92 9022 850 9Google Scholar

Suggested Reading

Bird, TD. Charcot-Marie-Tooth hereditary neuropathy overview. 1998 Sep 28 [updated 2023 Feb 23]. In Adam, MP, Mirzaa, GM, Pagon, RA, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2023. PMID: 20301532.Google Scholar
Corrado, B, Ciardi, G, Bargigli, C. Rehabilitation management of the Charcot-Marie-Tooth syndrome: a systematic review of the literature. Medicine (Baltimore) 2016;95(17):e3278. doi: 10.1097/MD.0000000000003278. PMID: 27124017; PMCID: PMC4998680.CrossRefGoogle ScholarPubMed
Klein, CJ. Charcot-Marie-Tooth disease and other hereditary neuropathies. Continuum (Minneap Minn) 2020;26(5):12241256. doi: 10.1212/CON.0000000000000927. Erratum in: Continuum (Minneap Minn). 2021 Feb 1;27(1):289. PMID: 33003000.Google ScholarPubMed
Kramarz, C, Rossor, AM. Neurological update: hereditary neuropathies. J Neurol 2022;269(9):51875191. doi: 10.1007/s00415-022-11164-1. Epub 2022 May 21. PMID: 35596796; PMCID: PMC9363318.Google ScholarPubMed
Nagappa, M, Sharma, S, Taly, AB. Charcot-Marie-Tooth disease. 2022 Aug 22. In StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023 Jan–. PMID: 32965834.Google Scholar
Zambon, AA, Pini, V, Bosco, L, et al. Early onset hereditary neuronopathies: an update on non-5q motor neuron diseases. Brain 2023;146(3):806822. doi: 10.1093/brain/awac452. PMID: 36445400; PMCID: PMC9976982.CrossRefGoogle ScholarPubMed

Suggested Reading

Abati, E, Manini, A, Velardo, D, et al. Clinical and genetic features of a cohort of patients with MFN2-related neuropathy. Sci Rep 2022;12(1):6181. doi: 10.1038/s41598-022-10220-0. PMID: 35418194; PMCID: PMC9008012.CrossRefGoogle ScholarPubMed
Cortese, A, Zhu Y, Rebelo AP et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020 May;52(5):473-481. doi: 10.1038/s41588-020-0615–4. Epub 2020 May 4.CrossRefGoogle Scholar

Suggested Reading

Farrugia, PR, Bednar, D, Oitment, C. Charcot arthropathy of the spine. J Am Acad Orthop Surg 2022;30(21):e1358e1365. doi: 10.5435/JAAOS-D-22-00212. Epub 2022 Aug 25. PMID: 36007201.Google ScholarPubMed
Fridman, V, Suriyanarayanan, S, Novak, P, et al. Randomized trial of L-serine in patients with hereditary sensory and autonomic neuropathy type 1. Neurology 2019;92(4):e359e370. doi: 10.1212/WNL.0000000000006811. Epub 2019 Jan 9. PMID: 30626650; PMCID: PMC6345118.CrossRefGoogle ScholarPubMed
González-Duarte, A, Cotrina-Vidal, M, Kaufmann, H, Norcliffe-Kaufmann, L. Familial dysautonomia. Clin Auton Res 2023;33(3):269280. doi: 10.1007/s10286-023-00941-1. Epub 2023 May 19. PMID: 37204536.CrossRefGoogle ScholarPubMed
Schwartzlow, C, Kazamel, M. Hereditary sensory and autonomic neuropathies: adding more to the classification. Curr Neurol Neurosci Rep 2019;19(8):52. doi: 10.1007/s11910-019-0974-3. PMID: 31222456.CrossRefGoogle ScholarPubMed
Sethi, PK, Sethi, NK. Charcot joint. Ann Neurol 2022;91(3):436437. doi: 10.1002/ana.26310. Epub 2022 Feb 10. PMID: 35084055CrossRefGoogle ScholarPubMed

Suggested Reading

Aimo, A, Castiglione, V, Rapezzi, C, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol 2022;19(10):655667. doi: 10.1038/s41569-022-00683-z. Epub 2022 Mar 23. PMID: 35322226.CrossRefGoogle ScholarPubMed
Carroll, A, Dyck, PJ, de Carvalho, M, et al. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 2022;93(6):668678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7. PMID: 35256455; PMCID: PMC9148983.CrossRefGoogle ScholarPubMed
Gillmore, JD, Gane, E, Taubel, J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021;385(6):493502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26. PMID: 34215024.CrossRefGoogle ScholarPubMed
Kaku, M, Berk, JL. Neuropathy associated with systemic amyloidosis. Semin Neurol 2019;39(5):578588. doi: 10.1055/s-0039-1688994. Epub 2019 Oct 22. PMID: 31639841.Google ScholarPubMed
Magrinelli, F, Fabrizi, GM, Santoro, L, et al. Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst Rev 2020;4(4):CD012395. doi: 10.1002/14651858.CD012395.pub2. PMID: 32311072; PMCID: PMC7170468.Google ScholarPubMed
Plante-Bordeneuve, V. Transthyretin familial amyloid polyneuropathy: an update. J Neurol 2018;265(4):976983. doi: 10.1007/s00415-017-8708-4. Epub 2017 Dec 16. PMID: 29249054.CrossRefGoogle ScholarPubMed
Wisniowski, B, Wechalekar, A. Confirming the diagnosis of amyloidosis. Acta Haematol 2020;143(4):312321. doi: 10.1159/000508022. Epub 2020 Jun 16. PMID: 32544917.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×